NeoProteomics (Sweden) Overview

  • Founded
  • 2000
Founded
  • Status
  • Out of Business
  • Employees
  • 3
Employees
  • Latest Deal Type
  • Out of Business
  • Financing Rounds
  • 3

NeoProteomics (Sweden) General Information

Description

Developer of biomarkers designed to aid sensitive and risk-free cancer diagnosis. The company's biomarkers provide risk-free cancer diagnosis by analyzing platelets role in cancer enabling its users to detect and diagnose various forms of aggressive cancer in which early diagnosis can significantly increase the survival rate of the disease.

Contact Information

Ownership Status
Out of Business
Financing Status
Formerly PE-Backed
Primary Industry
Biotechnology
Primary Office
  • Karolinska Sjukhuset / KI, Z5:2
  • 171 76 Stockholm
  • Sweden
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

NeoProteomics (Sweden) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore NeoProteomics (Sweden)‘s full profile, request access.

Request a free trial

NeoProteomics (Sweden) Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

NeoProteomics (Sweden) Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore NeoProteomics (Sweden)‘s full profile, request access.

Request a free trial